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Abstract
OBJECTIVES—To understand attitudes about and acceptance of anal Pap screening among men
who have sex with men (MSM).
METHODS—1742 MSM in the Multicenter AIDS Cohort Study (MACS) were offered free anal
Pap screening (cytology) and reported history of, attitudes about, and experience with anal Pap
screening. Predictors of declining screening were explored with multivariate logistic regression.
RESULTS—A history of ever having anal Pap screening was uncommon among HIV-uninfected
MSM, but more common among HIV-infected MSM (10% vs. 39%, p<0.001). Most participants
expressed moderate or strong interest in anal Pap screening (86%), no anxiety about screening
(66%), and a strong belief in the utility of anal Pap screening (65%). Acceptance of anal Pap
screening offered during this study was high (85%) across all four U.S. study sites. Among those
screened, most reported it was not a big deal, or not as bad as expected, while 3% reported it was
scary. Declining to have anal Pap screening was associated with Black race, anxiety specifically
about the screening, and low interest in screening, but not age or HIV status.
CONCLUSIONS—This study demonstrated high acceptance of anal Pap screening among both
HIV-infected and HIV-uninfected MSM across four U.S. study sites.
INTRODUCTION
In the past three decades, anal cancer incidence has increased 39% in women and 96% in
men in the U.S..1–3 In the general U.S. population, anal cancer incidence remains higher
among women than men (1.8 vs. 1.4 cases per 100,000 annually), but the incidence is
especially high among men who have sex with men (MSM) (35 per 100,000).4–6 Indeed,
data suggest anal cancer incidence among MSM may be similar to or higher than incidence
of cervical cancer among U.S. women prior to the introduction of cervical cytology
screening in the mid-1950s.1,7–13 Incidence estimates for HIV-infected MSM are even
higher and vary from 45.9/100,000 person-years14 in meta-analyses to 78.2/100,000 person-
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years15 for U.S. AIDS case surveillance and Surveillance Epidemiology and End Results
(SEER) data.
Human papillomavirus (HPV) infection is the major cause of anal cancer.14,16–18 Consistent
with the increased anal cancer incidence among MSM, anal HPV prevalence and incidence
are elevated among MSM compared to the general population.19,20 HIV-infected MSM have
even higher anal HPV prevalence, compared to HIV-uninfected MSM (98% vs. 57%).21,22
As effective antiretroviral therapy (ART, also referred to as HAART) helps HIV-infected
individuals live longer, more may now develop anal cancer.6,23,24 Based on initial studies, it
is unclear whether ART use reduces risk of anal intraepithelial neoplasia (AIN2/3,
precancer)25 or anal cancer,26,27 although low CD4 cell count does appear to increase risk of
anal cancer.28
Recent research suggests that anal Pap screening may have utility in preventing anal
cancer9,29–31 and is a cost-effective screening method for anal cancer prevention among
MSM32,33. Like cervical dysplasia, anal dysplasia is slow growing and treatable, and studies
suggest anal Pap tests can detect dysplasia with similar sensitivity and specificity to cervical
Pap tests.34–36 Based on these data and the success of cervical Pap screening in reducing
cervical cancer incidence, some have proposed routine anal Pap cytology (referred to as anal
Pap screening hereafter) among MSM.9,37 However, these guidelines remain preliminary as
researchers have not yet conducted a randomized trial to establish whether anal Pap
screening reduces anal cancer deaths. Further, recent studies suggest anal pre-cancers
(AIN2+) are relatively common among unscreened HIV-uninfected (~4%) and HIV-infected
(15–30%) MSM, much higher than anal cancer rates, so other researchers suggest that closer
examination of the relative harms and benefits of treating all AIN 2/3 in MSM is first
needed.36,38–42
Despite the high incidence of anal cancer among MSM and recommendations, by some, for
screening, MSM currently have low awareness of, access to, and use of anal Pap
screening.43,44 Indeed, in our previous research we observed a low reported prevalence of
ever having anal Pap screening among MSM. 45 The present study expands on these
previous findings by examining acceptance of screening when offered for free. We also
examine attitudes about anal Pap screening, experience with screening, and reasons for
declining to have an anal Pap.
METHODS
Participants and Recruitment
All men in the Multicenter AIDS Cohort Study (MACS) were eligible to participate in the
Anal Health Study. The MACS is an ongoing prospective study of HIV-infected and
uninfected MSM, recruited across four sites (Baltimore, Chicago, Pittsburgh, Los Angeles)
over three separate enrollment periods (1984–1985, 1987–1991 and 2001–2003), as
described previously.46,47 All MACS participants who attended any of their semiannual
MACS study visits between June 2010 – July 2011 ( MACS visits 53–55) were eligible to
be offered a free anal Pap test by study staff. Individuals who conducted phone interviews
only were not invited to participate.
Procedures
Participants completed a computer assisted self interview (CASI) baseline questionnaire 6
months before (52%) or just prior to (48%) being offered anal Pap screening. They were
offered an anal Pap test after receiving an informational brochure about screening, and had
an opportunity to ask study staff questions. Each participant undergoing screening provided
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written informed consent for the procedure. Participants completed a follow-up CASI
questionnaire at the next visit after they were offered anal Pap (usually 6 months later).
Measures
Anal Pap Acceptance and Decline—The primary outcome was Pap acceptance or
decline as documented by study staff.
Attitudes and Experiences with Anal Pap Screening—The baseline questionnaire
included history of anal Pap testing as well as attitudes such as anxiety about, interest in and
familiarity with anal Pap screening (Appendix). The follow-up questionnaire measured
experience related to receiving the screening or reasons for decline of the anal Pap test when
offered free of cost at a prior MACS visit (Appendix). Among men who declined screening,
87% provided a reason, and 13% left this question unanswered in the questionnaire.
Covariates—During each semiannual MACS visit self-administered and computer-aided
questionnaires assessed potential covariates.48 Demographic factors were age (<45, 45–54,
55–64, ≥65 years), study site, education (college degree: yes, no, unknown), individual
yearly income (≥$60,000, $20,000–$59,999, ≤$19,000), unknown/chose not to report), and
race/ethnicity (White non-Hispanic, Black non-Hispanic, and all others). Behavioral factors
were history of prior anal Pap test (yes, no) and number of anal receptive sex partners (0, 1–
2, and >2) in the past six months (defined as the number of sex partners with whom the
participant was the receptive partner). Health status indicators were HIV status/current CD4
cell count (HIV uninfected, HIV infected: CD4 ≥500, 300–499, and <300 cells/μL) and
current use of ART. Our analyses used covariate data from the same MACS visit at which
anal Pap screening was offered to participants.
Data Analyses
Chi-square tests were used to evaluate differences in categorical variables (Fischer’s exact
test used for small cell sizes) by HIV serostatus. Predictors of declining screening were
explored using univariate and multivariate logistic regression. Variables which were
statistically significant in the univariate model or were regarded as important in the literature
(age, income, college education, and HIV status/current CD4 cell count) were included in
multivariate models and were removed in a step-wise fashion; variables regarded as
important in the literature were retained in the final multivariate models regardless of
significance. All analyses were performed using STATA 11.0.
RESULTS
Analyses included data for 1742 men who were offered anal Pap screening as part of their
semi-annual MACS Study visit. These men represent 78% of all MACS participants in
active follow-up between June 2010 – July 2011. The other 504 men in active follow-up
were excluded from this study because they were not offered screening (usually because
they had reduced study visits due to time constraints or their interviews happened by phone,
Figure 1). Compared to men who were offered screening, men who were not offered
screening were younger, had lower current CD4 cell count, were more likely to be HIV-
infected, non-Hispanic Black or Other race, and to be from the Los Angeles study site
(Table 1).47,49,50 Our baseline questionnaire was completed by 95% (1662/1742) of the men
who were offered screening.
Anal Health Study participants were primarily non-Hispanic White (67%) or non-Hispanic
Black (20%), with a median age of 55 years (interquartile range=49–61), Table 1. Nearly
half of participants (47%) reported having a college degree, and only 3.7% had not
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completed high school or equivalent. The median annual gross income was between
$40,000–49,000. Among the HIV-infected men, 94% were currently taking ART, median
current CD4 cell count was 586 cells/μL (IQR=425–753), and 80% had HIV viral load
below the detectable level (≤40 RNA copies/mL). Of the 1742 men offered anal Pap
screening (Figure 1), there were 12 men with a confirmed history of anal cancer, including
11 of 820 HIV-infected men (prevalence=1.34%) and 1 of 922 HIV-uninfected man
(prevalence=0.11%).
Anal Health History and Attitudes Regarding Anal Pap Screening (Baseline Questionnaire)
Twenty-three percent of men (388/1662) reported ever having had anal Pap screening in the
past, an increase from 2007 when 11% of men in the MACS cohort had ever been screened.
In the present study, HIV-infected men were more likely to have been previously screened
compared to HIV-uninfected men (39% vs. 10%, p<0.001). Among those who reported
having been screened at least once, 51% (138/269) of HIV-infected and 14% (11/76) of
HIV-uninfected men reported having at least one abnormal Pap test result (p<0.001). Forty-
four percent of the 388 men who had ever had anal Pap screening reported the year they had
last been screened, and most (63%) of these 172 men had been screened within the past
three years. History of genital or anal warts was reported by 24% of participants. Very few
of these adult MSM reported being vaccinated with any doses of HPV vaccine (1.4%).
Although most men in the study had never had an anal Pap test, many participants reported
strong interest in screening (51%), no anxiety about screening (66%), and a strong belief in
the utility of anal Pap screening (65%). Specifically, only 14% of participants reported no
interest in anal Pap screening, and only 3% thought screening was not at all useful. HIV-
infected men were more likely than HIV-uninfected men to be very interested in (55% vs.
47%, p=0.007) and very familiar with (39% vs. 14%, p<0.001) anal Pap screening. HIV-
infected men were less likely than HIV-uninfected men to be not at all familiar with what is
involved with having an anal Pap (43% vs. 26%, p<0.001).
Complete lack of familiarity with the anal Pap test was reported more frequently by men in
Los Angeles (53%), compared to 36% of men in Baltimore, 29% of men in Chicago and
20% of men in Pittsburgh (p<0.001). High anxiety about anal cancer screening was
uncommon at all sites, ranging between 6–12% of men. Lack of interest (not at all
interested) in getting the anal Pap screening, the strongest risk factor for Pap decline, was
reported by 12%, 12%, 14% and 18% of participants in Baltimore, Chicago, Pittsburgh and
Los Angeles respectively.
Acceptance of Anal Pap screening
Overall, 85% of men accepted anal Pap screening when offered (Figure 1). Among those
screened in the study and who responded regarding the experience (n=886), a large majority
reported that they thought it was not a big deal (83%) and was not as bad as they expected
(62%), although 19% of participants reported they thought the procedure was uncomfortable
(Table 2). Among 214 men who reported anxiety about anal Paps in the pre-screening
questionnaire and subsequently were screened, 149 (70%) reported that the experience was
not as bad as expected. Reported experience with Pap was also similar among men who had
never been screened, and men who had been previously screened, including similarly high
rates reporting it was a not a big deal (82% vs 85, p=0.51), not as bad as expected (64% vs
58%, p=0.22), and similar moderate levels reporting it was uncomfortable (19% vs 18%,
p=0.91)
The primary reason reported for declining screening was already getting anal Pap testing
from another source/provider (68/263, 26%) (Table 2). Other reasons for not getting
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screening included: not having anal receptive sex (19%), expected discomfort during
screening or physical/emotional unpreparedness (17%), not interested in anal Pap screening
(13%), felt that they did not know enough about the screening (8%), or another reason
(apprehension over waiting for/knowing result of screening or resulting referral for follow-
up care; 3%).
History of anal Pap testing was similar among men in Baltimore (22%) and Los Angeles
(22%), slightly lower among those in Chicago (18%) and higher among those in Pittsburgh
(31%, p<0.001). Decline of the free anal Pap screening was low at all four MACS study
sites, ranging from 8% in Chicago to 26% in Pittsburgh, where the study has an active anal
dysplasia clinic, and men were more likely to have been recently screened. Getting an anal
Pap elsewhere was cited as the reason for declining to be screened in 26%–31% of men at
Pittsburgh, Los Angeles and Baltimore, but among only 4% of men in Chicago.
Correlates of Refusing (Deciding Not to Have) Anal Pap Screening
Analyses of factors associated with refusing anal Pap screening excluded 61 men who
decided not to be screened because they received Pap screening elsewhere. In univariate
analysis, declining anal Pap screening was associated with demographic factors (younger
age, non-Hispanic Black race, lower income, not having a college degree) and attitudinal
factors (anxiety about screening, lack of belief in the utility of screening, and lack of interest
in Pap screening), but not with HIV status, number of recent anal receptive sex partners, or
familiarity with anal Pap testing (Table 3). Screening acceptance was as high among men
who said they had never been screened before (88%) as among men who reported having
been screened in the past (92%).
In multivariate analysis, anal Pap refusal remained associated with non-Hispanic Black
ethnicity (OR=2.16, 95%CI=1.18–3.9), reported moderate anxiety (OR=1.68, 95%CI=1.01–
2.8) or high anxiety (OR=2.85, 95%CI=1.27–6.4) about screening, and being not at all
interested (OR=33, 95%CI=17–65) or only somewhat interested (OR=4.5, 95%CI=2.4–8.4)
in screening (Table 3). Correlates of Pap decline were similar when restricted to only men
expressing interest in screening (results not shown).
DISCUSSION
This study identified high acceptance of anal Pap screening when offered for free to MSM in
a multicenter U.S. study. Acceptance was equally high among both HIV-infected and HIV-
uninfected men. Although they were active participants of the MACS research study, the
majority of these men had never had anal Pap screening and were not very familiar with the
procedure. When given the opportunity to be screened, most expressed strong interest and
belief in its utility and chose to be screened. Furthermore, men who did and did not have a
history of prior anal Pap screening reported a similar, positive experience after the screening
suggesting that it was well tolerated by the majority of study participants.
These findings are consistent with reports published by others. For example, 82% of HIV-
infected Miami HIV-clinic attendees accepted anal cancer screening in a cross-sectional
study; however, rationale for accepting or declining screening was not evaluated in that
study51. Earlier MACS analyses (from 2007) showed 29% of participants reported they were
possibly or likely to get screened outside of the study in the following six months45.
However, our current analyses suggest that many of these men had not been screened in the
interval, but screening was accepted when offered conveniently and free of charge in our
study.
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The proportion of MSM who reported lack of familiarity with anal Pap testing was lower in
our study (35%) than two earlier studies, where 60–77% of MSM were not aware of what is
involved in anal Pap testing43,52, perhaps because we had previously asked them about this
topic. In one of the previous non-MACS studies, 63% of MSM reported they did not know
whether doctors recommend anal Pap testing for MSM43, which may be in part because
many MSM do not disclose their sexual behavior with men to their primary care providers.
In this study, familiarity with Pap testing varied by study site. Men in Pittsburgh, where the
study is associated with an active anal dysplasia clinic, were more likely to report familiarity
with anal Pap testing, and to decline anal Pap testing because they had already been recently
screened. Familiarity with Pap testing at study baseline was lower in Los Angeles than the
other study sites, which might represent regional differences in availability and awareness of
anal Pap screening53
Among the minority of men who declined screening, the most commonly reported reasons
were related to not having anal sex (suggesting they perceived themselves to be at lower
risk), concern about discomfort related to screening, and feeling like they did not know
enough about anal Pap testing. Studies evaluating barriers to anal cancer screening have also
reported that patient embarrassment, fear of discomfort during the procedure33 and primary-
care providers giving little emphasis to anal Pap testing43,54 are factors which may hinder
screening acceptance. However, distribution of informational packets on anal cancer and
Pap screening can improve anal Pap uptake55. Providing information may have contributed
to the high acceptance of anal cancer screening in our study, in which informational
brochures and knowledgeable staff were available to participants.
Although most participants were very interested in and not anxious about anal cancer
screening, men who reported low interest in or high anxiety about screening were, not
surprisingly, more likely to decline screening. Indeed, men who said they were not at all
interested in anal Pap screening at baseline, later cited reasons for decline of the free anal
Pap that mirrored this disinterest such as “I don’t have anal receptive sex” and “I don’t know
enough about it”. Our findings suggest that attitudes may explain declining anal Pap
screening when cost and availability needs are met. Attitudinal factors such as interest in
anal cancer screening, anxiety regarding the procedure and belief in the utility of anal cancer
screening should be considered when developing screening programs.
Once screened, most men reported a positive experience: among men who reported anxiety
about screening the majority reported the experience was not as bad as expected. Anal Pap
familiarity and refusal varied somewhat by study site, which is likely due to better
availability of Pap screening before the sub-study started at some sites. However, other
reasons for the variation may include comfort with the staff performing the exam or gender
of the examiner. Sites with only a female clinician anecdotally reported some men not
wanting to have an anal Pap performed by a female clinician.
Anal Pap testing, like cervical Pap testing, is known to have imperfect sensitivity and
specificity30,34,56 and therefore while it may be useful as a screening test it cannot be used
as a diagnostic test. Unfortunately, few providers have the technical expertise to perform
high resolution anoscopy (HRA), the diagnostic test for anal pre-cancer and cancer9,32. If
screening is found to have clear benefit in this community and use increases, it will be
critical to ensure an adequate supply of physicians trained to perform high resolution
anoscopy who can diagnose and treat individuals with abnormal Pap results.
This study has several limitations as well as strengths. We did not have data on participants’
experience surrounding previous anal Pap screening or on provider motivators for offering
or not offering screening. Also, screening history was self-reported and thus may reflect
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some recall errors. The completion rate for the follow-up survey was lower than desirable,
due to missing visits by some study participants, and limited time of other participants
leading to their not completing the survey. The study had several strengths including a
standardized protocol at all sites, a large well-characterized sample of HIV-uninfected and
HIV-infected MSM, and detailed behavioral and biologic data collection. Further the
prospective study design followed participants up to six months before and six months after
offering anal Pap screening. Participants in the MACS study might exhibit higher
acceptance rates than the general MSM population due in part to their participation in a
study on HIV and MSM health behaviors. However, the MACS cohort was recruited using
standard procedures based on network theory and social marketing from bars, organizations,
websites, and other community venues.46 As in other studies, study participants may differ
from non-participants, therefore the generalizability of our findings to other populations of
MSM will need to be established. Nevertheless our findings are informative among a
diverse, well-characterized sample of MSM from different geographical regions in the US.
This study provides new information about interest in and uptake of anal Pap screening, as
well as factors associated with screening. This study suggests that without cost and
availability barriers many MSM are interested in anal cancer screening, but modifiable
attitudinal factors may hinder some MSM from being screened. Additional research is
needed to clarify the benefits and harms of anal Pap testing. As abnormal anal cytology is
relatively common among MSM, it will be important to avoid overtreatment by having
appropriate referral and treatment algorithms, which need to be better outlined. If screening
is shown to be effective it will be important to ensure information about screening and Pap
screening for MSM are both available, especially at the point of primary care.
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Table 2
Reported experience with and reasons for declining (refusing) anal pap screening
All HIV-Infected HIV-Uninfected P-value
Reported experiences among those who accepted Pap screening N=886 N=395 N=491
 Not a big deal 734 (83%) 323 (82%) 411 (84%) 0.58
 Not as bad as expected 548 (62%) 254 (64%) 294 (60%) 0.32
 It was uncomfortable 164 (19%) 65 (16%) 99 (20%) 0.34
 It was scary 26 (3%) 16 (4%) 10 (2%) 0.18
 It was necessary 696 (79%) 337 (85%) 359 (73%) <0.001
Main reason for declining Pap N=263 N=123 N=140
 Already get anal Pap at other clinic 68 (26%) 47 (38%) 21 (15%) <0.001
 Don’t have anal receptive sex 51 (19%) 13 (11%) 38 (27%) 0.001
 Would feel uncomfortable/physically unprepared 46 (17%) 17 (14%) 29 (21%) 0.14
 Not interested 34 (13%) 22 (18%) 12 (9%) 0.03
 Don’t know enough about it 22 (8%) 6 (5%) 16 (11%) 0.06
 Don’t want to know if I have anal cancer/stress of waiting for results/cost and
burden of follow-up care
7 (3%) 1 (1%) 6 (4%) 0.08
 Did not report reason/did not recall why declined 35 (13%) 17 (14%) 18 (13%) 0.82
Note. Reported experience is for 886 screened participants who answered all five of the attitudinal items from the post-screening questionnaire
regarding their Pap testing experience in the Anal Health Study. Results were similar when another 183 screened individuals who only partially
answered the questionnaire (i.e., did not answer some questions) were included.
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Table 3
Univariate and multivariate predictors of decline (refusal) of anal Pap test when offered free of cost.
Declined Pap Univariate Multivariate




  ≥65 yrs 8/118 (7%) 1.00 1.00
  ≥55 and <65 yrs 33/413 (8%) 1.19 (0.54–2.7) 0.96 (0.40–2.3)
  ≥45 and <55 yrs 43/382 (11%) 1.74 (0.80–3.8) 1.17 (0.47–2.8)
  <45 yrs 33/178 (19%) 3.12 (1.39–7.0) 1.21 (0.46–3.2)
 Race and Ethnicity
  Non-Hispanic White 69/806 (9%) 1.00 1.00
  Non-Hispanic Black 37/185 (20%) 2.67 (1.75–4.1) 2.15 (1.18–3.9)
  All Other* 11/100 (11%) 1.32 (0.67–2.6) 1.46 (0.63–3.5)
 Individual Gross Income
  ≥$60,000 22/345 (6%) 1.00 1.00
  ≥$20,000 and <$60,000 38/350 (11%) 1.79 (1.03–3.1) 1.60 (0.84–3.0)
  ≤$19,000 48/242 (20%) 3.63 (2.12–6.2) 1.70 (0.83–3.5)
  Unknown 9/154 (6%) 0.91 (0.41–2.0) 0.95 (0.35–2.6)
 Degree/4 yrs college or higher
  Yes 56/605 (9%) 1.00 1.00
  No 53/316 (17%) 2.00 (1.32–3.0) 1.19 (0.71–2.0)
  Unknown 8/170 (4%) 0.48 (0.23–1.04) 0.48 (0.18–1.30)
 City of recruitment
  Los Angeles 22/308 (7%) 1.00 1.00
  Chicago 11/139 (8%) 1.12 (0.53–2.4) 0.90 (0.36–2.3)
  Baltimore 25/301 (8%) 1.18 (0.65–2.1) 1.93 (0.95–4.0)
  Pittsburgh 59/343 (17%) 2.70 (1.61–4.5) 3.04 (1.58–5.9)
Attitudes and Behaviors
 Anxious about anal Pap
  Not at all 62/735 (8%) 1.00 1.00
  Somewhat 41/274 (15%) 1.91 (1.25–2.9) 1.68 (1.01–2.8)
  Very 14/82 (17%) 2.23 (1.19–4.2) 2.83 (1.27–6.4)
 Interested in anal Pap
  Very 17/580 (3%) 1.00 1.00
  Somewhat 47/385 (12%) 4.61 (2.60–8.2) 4.49 (2.42–8.4)
  Not at all 53/126 (42%) 24.0 (13.2–43.7) 32.0 (16.3–62.7)
 Familiar with anal Pap
  Very 26/261 (10%) 1.00 -
  Somewhat 40/446 (9%) 0.89 (0.53–1.5) -
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Declined Pap Univariate Multivariate
N (%)^ OR (95%CI) OR (95%CI)
  Not at all 51/384 (13%) 1.38 (0.84–2.3) -
 Belief in utility of anal Pap
  High 60/713 (8%) 1.00 -
  Moderate 50/346 (14%) 1.84 (1.23–2.7) -
  No 7/32 (22%) 3.05 (1.27–7.3) -
 Ever had anal Pap
  No 93/800 (12%) 1.00 -
  Yes 24/291 (8%) 0.68 (0.43–1.09) -
 Recent Anal receptive sex
  Yes 50/535 (9%) 1.00 -
  No 67/556 (12%) 1.33 (0.90–2.0) -
Health Status
 HIV status & current CD4 cell count (cells/μL)
  HIV uninfected 71/605 (12%) 1.00 1.00
  HIV infected CD4 ≥ 500 28/303 (9%) 0.77 (0.48–1.21) 0.65 (0.37–1.13)
  HIV infected CD4 300–499 12/128 (9%) 0.78 (0.41–1.48) 0.60 (0.27–1.31)
  HIV infected CD4 <300 6/55 (11%) 0.92 (0.38–2.2) 0.56 (0.20–1.57)
^
 The results in this table are among 1,091 individuals with complete covariate data, an excluding 61 men who reported receiving screening
elsewhere as their reason for decline. Univariate results among all 1742 individuals offered anal Pap screening were similar to those among this
group with complete data. Bolded odds ratios are statistically significant (p<0.05).
*
“All Other” Race includes Hispanic Black/White (N=54) American Indian or Alaskan Native (N=4), Asian or Pacific Islander (N=5), Other non-
Hispanic (N=10), Other Hispanic (N=26) and did not report (N=1)
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